MCE | 8月最新快報

MCE | 8月最新快報


MedChemExpress - Master of Bioactive Molecules (Inhibitors. Screening Libraries. Proteins)

亞旭所代理的MedChemExpress (MCE) 提供多元的高品質研究化學品和生物化學品,包括超過 40,000 種用於實驗室和科學用途的新型生物活性化合物、染劑、胜肽和天然化合物。

CAS No.: 1443994-46-4


Research Area: Smad7 ASO/Crohn’s Disease

Mongersen TFA structure

An orally active SMAD7 antisense oligonucleotide.

Inhibits TGF-β1 pathways and alleviates Crohn’s disease.

CAS No.: 1709886-74-7


Research Area: Huntingtin Protein ASO/Huntington’s Disease

Tominersen structure

A second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production.

Used for the research of Huntington’s disease.

CAS No.: 2743427-26-9


Research Area: FAK Degrader

GSK215 structure

A selective PROTAC degrader of focal adhesion kinase (FAK).

Induces rapid and prolonged FAK degradation.

Long-lasting effect on FAK levels and a marked PK/PD disconnect.

Solubility: DMSO : 250 mg/mL (253.77 mM; Need ultrasonic)

CAS No.: 71145-03-4

Bay K 8644

Research Area: Calcium Channel Activator

Bay structure

A specific L-type Ca2+ channel agonist.

Increases Ca2+ influx through sarcolemmal Ca2+ channels by increasing the open time of the channel.

Possesses positive inotropic, vasoconstrictive and behavioral effects.

Solubility: DMSO : 83.33 mg/mL (233.88 mM; Need ultrasonic)

Dalpiciclib hydrochloride

Research Area: CDK/Breast Cancer/Eesophageal Squamous Cell Carcinoma

Anandamide structure

An orally active and highly selective inhibitor of CDK4/6.

Shows antitumor activity against breast cancer and esophageal squamous cell carcinoma.

Exerts antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.

Solubility: DMSO : 5 mg/mL (10.35 mM; ultrasonic and warming and heat to 60°C)

MCE EMA-Approved Drug Library/ FDA-Approved Anticancer Drug Library

Compound Library


EMA-Approved Drug Library

提供超過600 多種 EMA 核准具有高度藥理多樣性的藥物;

MCE EMA 核准的藥物庫可以作為藥物再利用的有用工具,可以加快藥物開發的速度。

FDA-Approved Anticancer Drug Library


MCE FDA 核准的抗癌藥物庫可用於發現新的抗癌藥物或作為用於抗癌研究的化合物,可以加速藥物開發的速度。

Natural products of microorganisms

1928年,Alexandra Fleming發現了青黴素,開創了微生物藥物的新領域。 在接下來的幾十年裡,微生物天然產物的藥物開發一直是新藥研發領域的熱門選擇。 微生物產生的次級代謝產物具有多種生物活性,可用作抗癌藥、抗寄生蟲藥、抗發炎藥、免疫抑製劑等,對人體健康發揮著重要作用。

Product Name



Stabilizes a complex between 14-3-3 and the stress response regulator GCN1, inducing GCN1 turnover and neurite outgrowth.


Inhibiting the phagocytosis of macrophages and the immune functions of other immune cells.

Aflatoxin M1

A major metabolite of Aflatoxin B1.

Manumycin A

Acting as a selective, competitive inhibitor of protein farnesyltransferase (FTase).


A potent photosensitizer, PKC inhibitor.

Latest Publications Citing Use of MCE Products

Covers of Recent Publications

2022 Jul;607(7917):135-141.

2022 May;605(7910):567-574.

2022 Jun 23;185(13):2234-2247.e17.

2022 Jul 7;S1074-7613(22)00280-1.

Cell Signaling Pathway



LINE 線上諮詢



error: Content is protected !!